This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yeh, K. C.
Right arrow Articles by Waldman, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yeh, K. C.
Right arrow Articles by Waldman, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1998, p. 332-338, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Single-Dose Pharmacokinetics of Indinavir and the Effect of Food

Kuang C. Yeh,1,* Paul J. Deutsch,1 Heidi Haddix,1 Michael Hesney,1 Vicki Hoagland,1 William D. Ju,1 Steven J. Justice,1 Barbara Osborne,2 Andrew T. Sterrett,1 Julie A. Stone,1 Eric Woolf,1 and Scott Waldman2,*

Merck Research Laboratories, West Point, Pennsylvania 19486,1 and Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 190172

Received 17 March 1997/Returned for modification 24 July 1997/Accepted 1 November 1997

Indinavir sulfate is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor indicated for treatment of HIV infection and AIDS in adults. The purpose of this report is to summarize single-dose studies which characterized the pharmacokinetics of the drug and the effect of food in healthy volunteers. Indinavir concentrations in plasma and urine were obtained by high-pressure liquid chromatography and UV detection assay methods. The results indicate that indinavir was rapidly absorbed in the fasting state, with the time to the maximum concentration in plasma occurring at ~0.8 h for all doses studied. Over the 40- to 1,000-mg dose range studied, concentrations in plasma and urinary excretion of unchanged drug increased greater than dose proportionally. The nonlinear pharmacokinetics were attributed to the dose-dependent oxidative metabolism of first-pass metabolism as well as to metabolism in the systemic circulation. Renal clearance slightly exceeded the glomerular filtration rate, suggesting a net tubular secretion component. At high concentrations in plasma, tubular secretion appeared to be lowered because there was a trend for a decreased renal clearance. Administration of 400 mg of indinavir sulfate following a high-fat breakfast resulted in a blunted and decreased absorption (areas under the concentration-time curves [AUCs], 6.86 µM·h in the fasted state versus 1.54 µM·h in the fed state; n = 10). However, two types of low-fat meals were found to have no significant effect on the absorption of 800 mg of indinavir sulfate (AUCs, 23.15 µM·h in the fasted state versus 22.71 and 21.36 µM·h, respectively, in the fed state; n = 11). Immediately following dosing, the concentrations of indinavir in urine often exceeded its intrinsic solubility. To reduce the risk of nephrolithiasis, it is recommended that indinavir sulfate be administered with water.

* Corresponding author and reprint requests: Kuang C. Yeh, W42-207, Merck Research Laboratories, West Point, PA 19486. Phone: (215) 652-6117. Fax: (215) 652-4524. E-mail: kuang_yeh{at}merck.com. Reprint requests: Scott Waldman, Division of Clinical Pharmacology, Jefferson University Hospital, Philadelphia, PA 19107.

Antimicrobial Agents and Chemotherapy, February 1998, p. 332-338, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Bulgheroni, E., Citterio, P., Croce, F., Lo Cicero, M., Vigano, O., Soster, F., Chou, T.-C., Galli, M., Rusconi, S. (2004). Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. J Antimicrob Chemother 53: 464-468 [Abstract] [Full Text]  
  • Dieleman, J. P., Sturkenboom, M. C. J. M., Jambroes, M., Gyssens, I. C., Weverling, G.-J., ten Veen, J. H., Schrey, G., Reiss, P., Stricker, B. H. Ch., for the ATHENA Study Group, (2002). Risk Factors for Urological Symptoms in a Cohort of Users of the HIV Protease Inhibitor Indinavir Sulfate: The ATHENA Cohort. Arch Intern Med 162: 1493-1501 [Abstract] [Full Text]  
  • Li, L. Y., Amidon, G. L., Kim, J. S., Heimbach, T., Kesisoglou, F., Topliss, J. T., Fleisher, D. (2002). Intestinal Metabolism Promotes Regional Differences in Apical Uptake of Indinavir: Coupled Effect of P-Glycoprotein and Cytochrome P450 3A on Indinavir Membrane Permeability in Rat. J. Pharmacol. Exp. Ther. 301: 586-593 [Abstract] [Full Text]  
  • Davis, D. A., Read-Connole, E., Pearson, K., Fales, H. M., Newcomb, F. M., Moskovitz, J., Yarchoan, R. (2002). Oxidative Modifications of Kynostatin-272, a Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor: Potential Mechanism for Altered Activity in Monocytes/Macrophages. Antimicrob. Agents Chemother. 46: 402-408 [Abstract] [Full Text]  
  • Sadler, B. M., Gillotin, C., Lou, Y., Eron, J. J., Lang, W., Haubrich, R., Stein, D. S. (2001). Pharmacokinetic Study of Human Immunodeficiency Virus Protease Inhibitors Used in Combination with Amprenavir. Antimicrob. Agents Chemother. 45: 3663-3668 [Abstract] [Full Text]  
  • Saah, A. J., Winchell, G. A., Nessly, M. L., Seniuk, M. A., Rhodes, R. R., Deutsch, P. J. (2001). Pharmacokinetic Profile and Tolerability of Indinavir-Ritonavir Combinations in Healthy Volunteers. Antimicrob. Agents Chemother. 45: 2710-2715 [Abstract] [Full Text]  
  • Kakuda, T. N., Page, L. M., Anderson, P. L., Henry, K., Schacker, T. W., Rhame, F. S., Acosta, E. P., Brundage, R. C., Fletcher, C. V. (2001). Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir. Antimicrob. Agents Chemother. 45: 236-242 [Abstract] [Full Text]  
  • Shelton, M. J., Mei, H., Hewitt, R. G., Defrancesco, R. (2001). If Taken 1 Hour before Indinavir (IDV), Didanosine Does Not Affect IDV Exposure, despite Persistent Buffering Effects. Antimicrob. Agents Chemother. 45: 298-300 [Abstract] [Full Text]  
  • Wintergerst, U., Kurowski, M., Rolinski, B., Müller, M., Wolf, E., Jaeger, H., Belohradsky, B. H. (2000). Use of Saliva Specimens for Monitoring Indinavir Therapy in Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 44: 2572-2574 [Abstract] [Full Text]  
  • Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., Manion, D. J., Ruiz, N. M., The Study 006 Team, (1999). Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults. NEJM 341: 1865-1873 [Abstract] [Full Text]  
  • Sadler, B. M., Hanson, C. D., Chittick, G. E., Symonds, W. T., Roskell, N. S. (1999). Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults. Antimicrob. Agents Chemother. 43: 1686-1692 [Abstract] [Full Text]  
  • Lin, J. H. (1998). Applications and Limitations of Interspecies Scaling and In Vitro Extrapolation in Pharmacokinetics. Drug Metab. Dispos. 26: 1202-1212 [Abstract] [Full Text]  
  • Hsu, A., Granneman, G. R., Cao, G., Carothers, L., Japour, A., El-Shourbagy, T., Dennis, S., Berg, J., Erdman, K., Leonard, J. M., Sun, E. (1998). Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers. Antimicrob. Agents Chemother. 42: 2784-2791 [Abstract] [Full Text]  
  • (1998). Food Can Affect Serum, Urine Indinavir Levels. JWatch Infect. Diseases 1998: 19-19 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»